Input to the PMPRB regarding development of new Guidelines Introduction

The following standing goals drive the BMC’s advocacy and inform its positions: • Effective models for meaningful, proactive, and impactful patient engagement in health and pharmaceutical policy development, recommendations and decision making, where patients and patient organizations are recognized as legitimate and integral contributors and patient-informed evidence is valued and incorporated. [...] Previously, BMC provided input as follows: the Draft Guidelines consultation in December 2022; the proposed Guideline revisions related to Gap medicines, comparator countries and international price tests in August 2021; the proposed Guideline Monitoring and Evaluation Plan in June 2021; the draft Guidelines in August and February 2020; the proposed reforms in February 2018 and June 2017; Health C. [...] In addition, to ensure a respectful and cooperative process, we request that the PMPRB seek to understand and consider the ethical guidelines patient organizations have in place to protect the independence of our work. [...] The PMPRB must provide opportunities for patient organizations to review and provide meaningful feedback to the PMPRB on both the guideline objectives and the impact assessment conducted by the PMPRB. [...] The BMC seeks timely access to a comprehensive range of medically necessary, safe, and effective drugs and related treatments, informed by patient-driven evidence and values, and delivered equitably and affordably to all patients in Canada.